Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. (Q44983950)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Rosiglitazone does not improve vascular function in subjects with chronic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Gerald Watts

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1

Doris T Chan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

4

Gursharan K Dogra

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

English

0 references

publication date

4 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

Nephrology Dialysis Transplantation

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

3543-3549

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21378155%20AND%20SRC:MED&resulttype=core&format=json

The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD.

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Thiazolidinediones as anti-inflammatory and anti-atherogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

European regulatory body recommends suspension of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Rosiglitazone is associated with mortality in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049

The emerging pleiotrophic role of adipokines in the uremic phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR049